Comparison of motor response to apomorphine and levodopa in Parkinson's disease

P A Kempster, J P Frankel, G M Stern, A J Lees

Abstract
The magnitude and pattern of motor responses to single doses of subcutaneous apomorphine and oral levodopa were compared in 14 patients with Parkinson's disease. Although apomorphine produced much shorter motor responses than levodopa, the quality of response to the two drugs was virtually indistinguishable. These clinical observations support the notion that integrity of striatal post-synaptic dopamine receptors is a key determinant of responsiveness to dopaminergic treatment in Parkinson's disease.

Many patients with Parkinson's disease develop unsatisfactory control of motor symptoms after prolonged treatment with levodopa. This may take the form of oscillating motor function, with periods of severe Parkinsonian disability alternating with periods of relative mobility marred by dyskinetic involuntary movements. Other patients show weaker responsiveness to levodopa and progressive deterioration of motor function without conspicuous fluctuations. Differences in the topography of motor deficits are apparent in some patients, and may be reflected in the pattern of responsiveness to levodopa and also in the pattern of levodopa induced involuntary movements. For example, severe gait freezing is resistant to levodopa in some patients although upper limb and cranial muscle function may show responsiveness, giving the impression of a patient who is "on" in the upper half of the body and "off" in the lower half of the body.

The neurochemical basis for such variations in clinical response to pharmacological treatment remains incompletely understood. Both pre-synaptic changes associated with capacity for surviving nigro-striatal terminals to synthesise, store and release dopamine formed from exogenous levodopa, and post-synaptic factors concerning preservation and sensitivity of striatal dopamine receptors may be of importance.

Apomorphine, a dopamine receptor agonist, has potent, rapid and therapeutically useful anti-Parkinsonian effects when injected subcutaneously. Apomorphine does not share transport or metabolic pathways with levodopa and probably acts by direct stimulation of striatal post-synaptic dopamine receptors. If, as has been suggested, responsiveness to levodopa depends on the metabolic and synaptic capacity of surviving pre-synaptic nigro-striatal terminals, one would expect to observe significant differences in the clinical effectiveness of the two agents in individual patients.

We have compared the magnitude and pattern of motor response to levodopa and apomorphine in 14 Parkinsonian patients using a variety of quantitative clinical parameters of motor function.

Patients and methods
Fourteen Parkinsonian patients (seven male, seven female) were studied. The mean age (range) was 57.1 years (43–68) and mean duration (range) of disease was 12.2 years (4–23). All patients were on chronic levodopa/decarboxylase inhibitor medication, mean treatment duration (range) being 9.8 years.

Table Summary of clinical details of all patients with modified Webster disability scale scores for levodopa and apomorphine studies. Severity of motor fluctuations: stable motor function (S), moderate motor fluctuations (+), severe oscillations (+++). Hoehn and Yahr grading refers to "off" state motor function.
Parkinsonian disability ranged from moderate to severe and 12 patients had symptomatic fluctuations of motor function, these being severe in nine. Mean "off" phase Hoehn and Yahr stage (range) was 3-3 (2-4). Clinical details are summarised in Table 1.

The studies were performed early in the morning after all anti-Parkinsonian medication had been withheld overnight. On one day, an oral dose of levodopa 250 mg/carbidopa 25 mg was administered and on a second day, a subcutaneous injection of apomorphine. Mean apomorphine dose was 2 mg (1-4 mg), dose was determined in each case by doubling a previously established threshold dose for motor response. Studies were not necessarily performed on consecutive days. All patients were given domperidone 20 mg by mouth two hours before the apomorphine injection and remained fasting for the duration of the levodopa and apomorphine studies.

Motor function was assessed at five to 15 minute intervals following levodopa or apomorphine administration and continued until after the motor response had worn off, as judged by pre-dose baseline motor scores. The following assessments were performed as described previously: unilateral hand tapping count over 30 seconds, timed walking over a 12 metre distance (failure to complete the task within 30 seconds was recorded as 30 seconds) and scoring of severity of tremor according to a four point scale.

Dyskinetic involuntary movements were scored on a similar four point scale for each of six anatomical zones (each limb, cranio-cervical, trunk) giving a maximum dyskinesia score of 24. In addition, patients were scored in pre-dose "off" phases and at time of peak motor response using a modified Webster disability scale evaluation of twelve domains of Parkinsonian disability with a maximum disability score of 36. The amplitude of motor response was calculated for each motor parameter by subtracting pre-dose "off" motor score from the best score obtained during the subsequent "on" period.

Statistical significance was assessed by Student’s t test with comparison of paired data. Linear correlation coefficients were calculated to examine amplitude of motor response and "on" period motor scores for levodopa and apomorphine.

Results

All parameters of motor function showed close correlation between apomorphine and levodopa for both amplitude of motor response and best "on" period motor function. The mean amplitude of hand tapping count response was 18 for apomorphine and 20 for levodopa (r = 0.92, p < 0.001) and mean peak "on" phase tapping scores were 47 for apomorphine and 48 for levodopa (r = 0.89, p < 0.001) (Fig 1). Mean walking time response amplitude was -12.5 s for apomorphine and -12.3 s for levodopa (r = 0.81, p < 0.001) and mean best "on" walking time was 12.1 s for apomorphine and 11.1 s for levodopa (r = 0.80, p < 0.001). No patient had dyskinesia when "off" or tremor when "on", so amplitude and "on" scores for these motor parameters were the same. Mean apomorphine dyskinesia amplitude was 0-6 and mean levodopa dyskinesia amplitude was 7.0 (r = 0.92, p < 0.001). Mean apomorphine tremor amplitude was -0-9 and mean levodopa tremor amplitude was -1.1 (r = 0.90, p < 0.001). Mean modified Webster score amplitude was -14.2 for apomorphine and -14.7 for levodopa (r = 0.96, p < 0.001) and mean "on" phase Webster score was 6-9 for both drugs (r = 0.98, p < 0.001) (Table 1).

There was no statistically significant difference in mean response amplitude or "on" phase scores between the two drugs for any motor parameter.

Figure 1 Correlation of pre-dose (open circles) and peak motor response (closed circles) hand tapping counts for apomorphine and levodopa.

Figure 2 Serial hand tapping, walking and dyskinesia scores in Case 2 in relation to levodopa and apomorphine doses. Both drugs produce a similar biphasic pattern of dyskinetic involuntary movements.
Not only was the overall magnitude of the response similar for apomorphine and levodopa, but both agents produced an almost identical pattern of response so far as the topography of motor deficits and dyskinesia in individual patients was concerned. The relative responsiveness of upper limbs (hand tapping) and gait function (walking time) in each case was the same for both drugs. One patient (Case 7) had a degree of drug resistant gait freezing which limited walking time improvement in “on” phases following both apomorphine and levodopa administration. Another patient (Case 2) usually had biphasic dyskinetic involuntary movements on oral levodopa medication. The single dose levodopa and apomorphine studies both showed a biphasic pattern of dyskinesia with similar topography and severity of involuntary movements.

Mean duration (range) of motor response to apomorphine injection was 56 minutes (30–80) compared with 211 minutes (140–315) for oral levodopa. Time to onset varied between three and 14 minutes (mean 7.9) for apomorphine and 19 and 75 minutes (mean 35.4) for levodopa. There was a weak correlation for duration of motor response for the two drugs (r = 0.45, p < 0.5) and none for time to onset of response (r = 0.16).

In 12 cases a transient deterioration in hand tapping performance to below pre-dose baseline level was observed following wearing off of motor response to both levodopa and apomorphine. Mean pre-dose to post-motor response tapping count ratio was 28 to 19 for levodopa (p < 0.01) and 29 to 22 for apomorphine (p < 0.001).

Discussion

The magnitude of clinical response and topography of response pattern to levodopa and apomorphine appear to be virtually identical in individual patients. Intensity, topography and time course of dyskinetic movements show similar parallels between the two agents, allowing for a shorter overall duration of motor response to apomorphine. Our results did not confirm specific effectiveness of apomorphine in reducing dyskinesia or Parkinsonian tremor.7,8 We also observed transient worsening of the Parkinsonian state to below pre-dose level at the conclusion of motor responses. This phenomenon has previously been described for levodopa and may represent a transient inhibitory effect of low or declining plasma levodopa levels.7 Apomorphine and levodopa appear to have similar capacity to produce this response pattern in individual patients.

Animal experimental data suggests that apomorphine exerts its anti-Parkinsonian effects by direct interaction with striatal post-synaptic dopamine receptors. Apomorphine administration actually suppresses firing rate, and presumably synaptic dopamine release, in nigro-striatal neurons by stimulating pre-synaptic dopamine receptors.9,10 The equivalence of clinical response to apomorphine and levodopa argues against a fundamentally different mechanism of action for levodopa involving physiological restoration of synaptic dopaminergic neurotransmission by surviving nigro-striatal terminals. Were this true, it would be expected that differences in response amplitude between the two agents would be found, particularly in patients with advanced disease and more severe loss of nigral neurons. Our findings are more compatible with Melamed’s proposal of a “non-physiological” action of levodopa.12 He had suggested that exogenous levodopa may undergo biotransformation to dopamine at miscellaneous sites within the striatum, escape into the extracellular space and interact with post-synaptic dopamine receptors independently of synaptic activity in remaining nigro-striatal terminals. A corollary to this concept that levodopa and dopamine receptor agonist agents share similar striatal pharmacodynamics is that the capacity for individual patients to respond to dopamine receptor stimulating pharmacological treatment is determined by post-synaptic factors, especially striatal dopamine receptor status. While severity of nigral cell loss and hence striatal endogenous dopamine deficiency probably defines “off” state disability, it is proposed that “on” phase motor function and amplitude of motor response depends on preservation and sensitivity of striatal post-synaptic dopamine receptors, if essential non-dopaminergic components of the extrapyramidal motor system are intact.

The practical importance of these studies concerns the assessment of the goals of pharmacological treatment in individual Parkinsonian patients. Amplitude of motor response to levodopa (or apomorphine) can be readily assessed by observing motor function in “off” and “on” states in relation to a single dose. Although some long phase variation in levodopa responsiveness can occur, such assessments indicate the best motor function attainable with drug therapy. Successful pharmacological manipulation will result in increased “on” state duration per day but will not substantially improve the quality of “on” states. Patients who respond only weakly to levodopa cannot be expected to show a greater response to other agents or other modes of administration. Similarly, aspects of Parkinsonian disability in individual patients, such as gait freezing, which do not respond to test doses of levodopa are likely to be resistant to other forms of dopaminergic drug treatment.

PAK and JPF were supported by the Kate Stillman Research Fellowship.


Downloaded from http://jnnp.bmj.com/ on June 24, 2017 - Published by group.bmj.com
Comparison of motor response to apomorphine and levodopa in Parkinson's disease


Comparison of motor response to apomorphine and levodopa in Parkinson's disease.
P A Kempster, J P Frankel, G M Stern and A J Lees

J Neurol Neurosurg Psychiatry 1990 53: 1004-1007
doi: 10.1136/jnnp.53.11.1004

Updated information and services can be found at:
http://jnnp.bmj.com/content/53/11/1004

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/